OnCusp Therapeutics
PrivateLast Round
Series A
Jan 4, 2024
Total Funding Raised
$139M
Company Overview
OnCusp Therapeutics is an oncology company that develops innovative, first-in-class cancer therapies by translating preclinical research into clinical treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OnCusp Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
OnCusp Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 4, 2024 | ||||
| Seed | Aug 1, 2022 | ||||
| Seed | Apr 1, 2021 |
Key People
Founding team and executive leadership
OnCusp Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series A, Seed |
| F-Prime Capital | Series A |
| OrbiMed | Series A |
| Catalio Capital Management | Series A |
| Forge Life Science Partners | Series A |
| HongShan | Seed |
| Novo Holdings | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 23, 2025
Dimitry S.A. Nuyten appointed as the new Chief Medical Officer.
- Jun 2, 2025
Presented Phase 1a results for CUSP06 at the 2025 ASCO Annual Meeting.
OnCusp Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about OnCusp Therapeutics's valuation, stock price, and market status.